Sep 25, 2024, 08:00 ET – Type B meeting with FDA held under Breakthrough Therapy designation resulted in agreement on key aspects of Phase 3 trial design – Single Phase 3 trial designed to enroll 200 U.S. patients with a 90-day survival primary endpoint; topline results expected within two years of trial initiation – Protocol for Phase 3 […]
Sep 04, 2024, 16:30 ET CUPERTINO, Calif., Sept. 4, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced management’s participation in the H.C. Wainwright 26th Annual Global Investment Conference
DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference Read More »
Aug 13, 2024, 16:01 ET – FDA Granted Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis – Held Type B Meeting with FDA to Discuss Phase 3 Clinical Trial Design – Seeking to Initiate Phase 3 Trial in 2024 with Topline Results Expected in 2H 2026 – Webcast of Earnings Call
DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update Read More »
Aug 07, 2024, 16:30 ET CUPERTINO, Calif., Aug. 7, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its second quarter financial results on Tuesday, August
May 21, 2024, 08:00 ET DURECT plans to confirm the efficacy and safety of larsucosterol in a registrational Phase 3 clinical trial CUPERTINO, Calif., May 21, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute
May 13, 2024, 16:05 ET – FDA Feedback Supports Single Pivotal Trial for Approval of Larsucosterol in Alcohol-Associated Hepatitis – Webcast of Earnings Call Today, May 13th at 4:30 p.m. ET CUPERTINO, Calif., May 13, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31,
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update Read More »
May 07, 2024, 16:30 ET CUPERTINO, Calif., May 7, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its first quarter financial results on Monday, May
Apr 30, 2024, 07:00 ET CUPERTINO, Calif., April 30, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced acceptance of a late-breaking oral presentation at the European Association for
27 Mar, 2024, 16:01 ET – Ongoing Communication with FDA to Align on Next Steps for Larsucosterol in Alcohol-Associated Hepatitis – Webcast of Earnings Call Today, March 27th at 4:30 p.m. ET CUPERTINO, Calif., March 27, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the fourth quarter and year ended December
20 Mar, 2024, 16:30 ET CUPERTINO, Calif., March 20, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its fourth quarter and full year 2023
